These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Population immunity to polioviruses in the context of a large-scale wild poliovirus type 1 outbreak in Tajikistan, 2010. Khetsuriani N; Pallansch MA; Jabirov S; Saparova N; Oberste MS; Wannemuehler K; Ursu P; Wassilak S; Martin R Vaccine; 2013 Oct; 31(42):4911-6. PubMed ID: 23891502 [TBL] [Abstract][Full Text] [Related]
3. Seroprevalence of poliovirus antibodies in Nigeria: refining strategies to sustain the eradication effort. Bolu O; Adamu U; Franka R; Umeokonkwo CD; An Q; Greby S; McDonald S; Mainou B; Mba N; Agala N; Archer WR; Braka F; Etapelong SG; Gashu TS; Siddique AR; Asekun A; Okoye M; Iriemenam N; Wiesen E; Swaminathan M; Ihekweazu C; Shuaib F Pan Afr Med J; 2023; 45(Suppl 2):2. PubMed ID: 38370104 [TBL] [Abstract][Full Text] [Related]
4. A study evaluating poliovirus antibodies and risk factors associated with polio seropositivity in low socioeconomic areas of Pakistan. Habib M; Soofi S; Ali N; Sutter RW; Palansch M; Qureshi H; Akhtar T; Molodecky NA; Okayasu H; Bhutta ZA Vaccine; 2013 Apr; 31(15):1987-93. PubMed ID: 23429005 [TBL] [Abstract][Full Text] [Related]
5. Assessment of seroprevalence against poliovirus among Italian adolescents and adults. Lupi S; Stefanati A; Baldovin T; Roman A; Baldo V; Gabutti G Hum Vaccin Immunother; 2019; 15(3):677-682. PubMed ID: 30427738 [TBL] [Abstract][Full Text] [Related]
6. Poliovirus neutralizing antibody levels among individuals in three regions of Ghana. Opare JK; Akweongo P; Afari EA; Odoom JK Ghana Med J; 2019 Jun; 53(2):170-180. PubMed ID: 31481814 [TBL] [Abstract][Full Text] [Related]
7. A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people. Kim HJ; Hwang S; Lee S; Kwon Y; Park K; Park YJ; Bae GR; Lee SW; Jeong YS; Hyeon JY BMC Infect Dis; 2015 Mar; 15():164. PubMed ID: 25881203 [TBL] [Abstract][Full Text] [Related]
8. Lower immunity to poliomyelitis viruses in Australian young adults not eligible for inactivated polio vaccine. Hendry AJ; Beard FH; Dey A; Quinn H; Hueston L; Dwyer DE; McIntyre PB Vaccine; 2020 Mar; 38(11):2572-2577. PubMed ID: 32037225 [TBL] [Abstract][Full Text] [Related]
9. Deficiency of immunity to poliovirus type 3: a lurking danger? Reinheimer C; Friedrichs I; Rabenau HF; Doerr HW BMC Infect Dis; 2012 Jan; 12():24. PubMed ID: 22280025 [TBL] [Abstract][Full Text] [Related]
10. Assessment of poliovirus antibody seroprevalence in polio high risk areas of West Africa. Guindo O; Mach O; Doumbia S; Ekra DK; Beavogui AH; Weldon WC; Oberste MS; Sutter RW Vaccine; 2018 Feb; 36(8):1027-1031. PubMed ID: 29358054 [TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017. Hussain I; Mach O; Hamid NA; Bhatti ZS; Moore DD; Oberste MS; Khan S; Khan H; Weldon WC; Sutter RW; Bhutta ZA; Soofi SB Vaccine; 2018 Apr; 36(15):1921-1924. PubMed ID: 29510918 [TBL] [Abstract][Full Text] [Related]
12. Sero-survey of polio antibodies and quality of acute flaccid paralysis surveillance in Chongqing, China: A cross-sectional study. Xu J; Kuang S; Rong R; Zhang Y; Tang W; Wang Q Medicine (Baltimore); 2020 Jul; 99(31):e21298. PubMed ID: 32756110 [TBL] [Abstract][Full Text] [Related]
13. Epidemiological serosurvey of poliovirus in Guangdong, China: A cross-sectional study. Tan Q; Zhu Q; Zheng H; Zhang B; Wu C; Guo X; Li H; Liu L; Liu Y; Rutherford S; Zheng H Hum Vaccin Immunother; 2018; 14(11):2644-2648. PubMed ID: 30059644 [TBL] [Abstract][Full Text] [Related]
14. Seroprevalence of poliovirus antibodies amongst children in Zaria, Northern Nigeria. Giwa FJ; Olayinka AT; Ogunshola FT Vaccine; 2012 Nov; 30(48):6759-65. PubMed ID: 23000220 [TBL] [Abstract][Full Text] [Related]
15. Survey of poliovirus antibodies during the final stage of polio eradication in Egypt. El-Sayed N; Al-Jorf S; Hennessey KA; Salama M; Watkins MA; Abdelwahab JA; Pallansch MA; Gary H; Wahdan MH; Sutter RW Vaccine; 2007 Jun; 25(27):5062-70. PubMed ID: 17543428 [TBL] [Abstract][Full Text] [Related]
16. Long-term persistence of poliovirus neutralizing antibodies in the era of polio elimination: An Italian retrospective cohort study. Bianchi FP; Larocca AMV; Bozzi A; Spinelli G; Germinario CA; Tafuri S; Stefanizzi P Vaccine; 2021 May; 39(22):2989-2994. PubMed ID: 33933314 [TBL] [Abstract][Full Text] [Related]
17. Immunity status against poliomyelitis in young migrants: a seroprevalence study. Veronesi L; Colucci ME; Capobianco E; Bracchi MT; Zoni R; Palandri L; Affanni P Acta Biomed; 2019 Sep; 90(9-S):28-34. PubMed ID: 31517887 [TBL] [Abstract][Full Text] [Related]
18. Factors contributing to outbreaks of wild poliovirus type 1 infection involving persons aged ≥15 years in the Democratic Republic of the Congo, 2010-2011, informed by a pre-outbreak poliovirus immunity assessment. Alleman MM; Wannemuehler KA; Weldon WC; Kabuayi JP; Ekofo F; Edidi S; Mulumba A; Mbule A; Ntumbannji RN; Coulibaly T; Abiola N; Mpingulu M; Sidibe K; Oberste MS J Infect Dis; 2014 Nov; 210 Suppl 1():S62-73. PubMed ID: 25316879 [TBL] [Abstract][Full Text] [Related]
19. Is Italian population protected from Poliovirus? Results of a seroprevalence survey in Florence, Italy. Giammanco GM; Bechini A; Urone N; Bonura F; Li Muli S; De Grazia S; Bellini I; Tiscione E; Boccalini S; Nastasi A Hum Vaccin Immunother; 2018; 14(9):2248-2253. PubMed ID: 29771600 [TBL] [Abstract][Full Text] [Related]
20. Immunity to poliomyelitis in The Netherlands. Conyn-Van Spaendonck MA; de Melker HE; Abbink F; Elzinga-Gholizadea N; Kimman TG; van Loon T Am J Epidemiol; 2001 Feb; 153(3):207-14. PubMed ID: 11157405 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]